Sun Yuzhang, Hu Xiaofeng, Xu Changhao, Zhang Menghe, Wu Shaohui, Qin Mu, Liu Xu, Dong Yujiang
Graduate School, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, P.R. China.
Department of Cardiology, Shanghai Jiao Tong University Affiliated Chest Hospital, Shanghai 200030, P.R. China.
Exp Ther Med. 2024 Aug 23;28(5):407. doi: 10.3892/etm.2024.12696. eCollection 2024 Nov.
The present study investigated the synergistic effects of radiofrequency ablation and various anticoagulants on adverse outcomes in patients with atrial fibrillation (AF) and left atrial appendage thrombosis following successful thrombolysis. Patients diagnosed with AF and left atrial appendage thrombosis post-successful thrombolysis (n=92) were retrospectively analysed. They were divided into two groups: Group A received radiofrequency ablation combined with an anticoagulant, while Group B received an anticoagulant alone and in combination with antiarrhythmic drugs. Subgroup analyses were conducted based on left atrial diameter (>45 mm), duration of AF (>1 year) and types of anticoagulants. Univariate and multivariate logistic regression analyses were performed to assess stroke and mortality risks in patients with AF with left atrial appendage thrombosis after dissolution. Multivariate logistic regression analysis identified AF duration (>1 year), left atrial diameter (>45 mm) and BNP level as significant risk factors for stroke (P<0.05). Compared with NOACs, the traditional anticoagulants (warfarin) demonstrated higher survival rates and lower stroke incidence in Group B (P<0.05); however, no significant difference was observed within Group A (P>0.05). Radiofrequency ablation combined with anticoagulants appeared to be more effective in treating AF with left atrial appendage thrombosis post-dissolution compared with anticoagulants alone. Attention to AF duration and left atrial diameter is crucial during early patient management. However, the choice between warfarin or NOACs for patients with AF and left atrial appendage thrombosis warrants further investigation.
本研究调查了射频消融与各种抗凝剂对成功溶栓后房颤(AF)和左心耳血栓形成患者不良结局的协同作用。对确诊为成功溶栓后房颤和左心耳血栓形成的患者(n = 92)进行回顾性分析。他们被分为两组:A组接受射频消融联合抗凝剂治疗,而B组仅接受抗凝剂治疗,并联合抗心律失常药物。根据左心房直径(>45 mm)、房颤持续时间(>1年)和抗凝剂类型进行亚组分析。进行单因素和多因素逻辑回归分析,以评估成功溶栓后房颤合并左心耳血栓形成患者的中风和死亡风险。多因素逻辑回归分析确定房颤持续时间(>1年)、左心房直径(>45 mm)和BNP水平是中风的显著危险因素(P<0.05)。与非维生素K拮抗剂口服抗凝药(NOACs)相比,传统抗凝剂(华法林)在B组中显示出更高的生存率和更低的中风发生率(P<0.05);然而,A组内未观察到显著差异(P>0.05)。与单独使用抗凝剂相比,射频消融联合抗凝剂在治疗成功溶栓后合并左心耳血栓形成的房颤方面似乎更有效。在患者早期管理过程中,关注房颤持续时间和左心房直径至关重要。然而,对于房颤合并左心耳血栓形成的患者,在华法林或NOACs之间的选择值得进一步研究。